Company recurring revenue segment revenue up 13% for the nine months ended September 30, 2019 over comparable period in 2018 Company recurring revenue segment gross margins for.
It's been a sad week for STRATA Skin Sciences, Inc. (NASDAQ:SSKN), who've watched their investment drop 15% to US$1.16...
HORSHAM, Pa., March 10, 2020 -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated.
HORSHAM, Pa., April 06, 2020 -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated.
Q1 2020 STRATA Skin Sciences Inc Earnings Call
Recurring revenues grew 12.6% in 2019Total gross margins increased 6.9% in 2019Global recurring revenue installed base totaled 830 systems at year end 2019 Conference call and.
Q4 2019 STRATA Skin Sciences Inc Earnings Call
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]
In an effort to conserve cash, the Company has put employees who either cannot work from home or cannot work due to the COVID-19 related shutdowns on leave of absence with the expectation that when exercising its COVID-19 “exit strategy” and resumes its business, the Company will bring these employees back. Additionally, the Company has reduced materially all of its discretionary spending, including direct to consumer advertising, marketing, sales and travel, which the Company believes would save approximately $1.0 million in additional cash outlays per quarter. Lastly, the Company has worked closely with its vendors in order to manage payments and inventory receipts to further conserve its cash position, which the Company believes would reduce cash outlays by approximately $1.2 million per quarter, as long as there is no need in manufacturing additional devices for placement.
NEW YORK, NY / ACCESSWIRE / March 17, 2020 / STRATA Skin Sciences, Inc. (NASDAQ:SSKN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 17, 2020 at ...
HORSHAM, Pa., Nov. 14, 2019 -- STRATA Skin Sciences (NASDAQ: SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to developing,.
The actions are among several moves the company has taken to conserve cash during the Covid-19 pandemic.
Recurring revenue for the first quarter of 2020 grew 7.3% over first quarter 2019Total gross margins in the first quarter of 2020 grew 3.8% over first quarter 2019 Global.
The XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light and is cleared to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma – skin diseases that impact over 35 million patients in the United States alone. The different platforms (Ultra, Velocity and now Momentum) offer clinical providers functionality and usability to support the thousands of domestic and international devices. Named Momentum, the cleared platform creates the foundation for the upcoming technological developments in the Company’s worldwide install base.
Preliminary, unaudited Q4 2019 revenues in the range of $8.8 million to $8.85 million, as compared to $8.0 million in the fourth quarter of 2018. Preliminary, unaudited Q4 2019 recurring revenue in the range of $6.5 million to $6.55 million as compared to $5.87 million in the fourth quarter of 2018.
The PPP loan matures on May 1, 2022 and bears an interest rate of 1.0% per annum. All or a portion of the PPP loan may be forgiven by the lender upon application by STRATA beginning 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the requirements set forth by the Small Business Administration (the “SBA”) pursuant to the CARES Act. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, covered mortgage interest and covered utilities during the eight week period beginning on the date of disbursement of proceeds from the PPP loan.
STRATA Skin Sciences, Inc. (SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced that it has been granted an extension to its stay of suspension from Nasdaq. The Company will continue to trade pending a hearing on November 21, 2019, following which the Nasdaq Hearings Panel will make a decision about the Company’s listing based on its full and complete record at that time. To be in full compliance with the Nasdaq listing requirements, the Company must be current with its Annual and Quarterly Reports on Forms 10-K and 10-Q, respectively, with the SEC.
HORSHAM, Pa., Nov. 19, 2019 -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated.
HORSHAM, Pa., May 05, 2020 -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company in Dermatology and Plastic Surgery dedicated.
The new loan, at a fixed interest rate of 2.79%, significantly lowers the Company’s interest expense for 2020. The proceeds of the new loan facility were used to repay the Company’s outstanding term note with MidCap Financial.